ArticleInternational journal of surgery (London, England)2026
Plasma proteomic markers predict risk for bowel resection in inflammatory bowel disease: a retrospective cohort study.
Article in International journal of surgery (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBowel resection is required in up to 27% of inflammatory bowel disease (IBD) patients due to severe complications. Identifying reliable predictors for future surgery is crucial for risk stratification and management. MATERIALS AND
methodsWe retrospectively analyzed UK Biobank data of IBD patients with plasma proteomics measured using the Olink platform. A Random Survival Forest (RSF) model was used to evaluate the predictive performance of inflammatory proteins for surgical risk. The concordance index (C-index) compared Olink-based and conventional clinical models. A predicted risk score quantified individual surgery risk, and Kaplan-Meier analysis assessed differences in surgery-free survival between high- and low-risk groups. Cox proportional hazards models verified the independent predictive value of proteomics.
resultsAmong 915 patients with IBD, 81 cases underwent bowel resection during follow-up. The RSF model using Olink proteins achieved a superior C-index compared to conventional markers (0.784 vs 0.543, P < 0.01). Key predictors included IL15, PAPPA, and PIK3AP1. Patients with a higher predicted risk score had a significantly higher surgery risk ( P < 0.0001). The predicted risk score remained an independent predictor for surgery risk [adjusted HR: 0.83, 95% confidence interval (CI): 0.81-0.86]. The net reclassification analysis demonstrated improved patient-level stratification by proteomic features beyond standard clinical predictors (net reclassification improvement: 0.096, 95% CI: 0.008-0.257, P = 0.027).
conclusionPlasma proteomic markers demonstrated superior predictive performance over traditional markers in assessing future bowel resection risk in IBD. Incorporating proteomics into clinical practice could enhance risk stratification and inform early interventions to reduce surgical burdens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.